Vanguard Group Inc Cytokinetics Inc Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 11,849,547 shares of CYTK stock, worth $359 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,849,547
Previous 11,915,821
0.56%
Holding current value
$359 Million
Previous $561 Million
15.04%
% of portfolio
0.01%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$444 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$301 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$242 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$184 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.07MShares$93.1 Million4.32% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $2.85B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...